CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
VP-102 Cantharidin topical film forming solution +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03487549
NCT03487549Phase 2Completed
CompareCT.gov

A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)

Verrica Pharmaceuticals Inc.·interventional·Posted Apr 4, 2018·Updated Nov 27, 2024

In Brief

A Phase 2 clinical trial evaluating VP-102 Cantharidin topical film forming solution and VP-102 Cantharidin, topical film forming solution for Common Wart and 11 related conditions. Completed, enrolled 56 participants across 5 sites.

Detailed Summary

This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common warts. This study has two Cohorts.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Wart, Warts Hand, Warts, Papillomavirus Infections, DNA Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Virus Diseases, Tumor Virus Infections, Verruca Vulgaris, Verruca
CountriesUnited States
CollaboratorsInstat Consulting, Inc., Paidion Research, Inc., BioClinica, Inc., ALMAC Clinical Services

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 4, 2018
Enrollment StartMar 27, 2018
Primary CompletionMay 16, 2019
Study CompletionJul 15, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.2 years ago

Interventions

VP-102 Cantharidin topical film forming solutioncombination

VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.

VP-102 Cantharidin, topical film forming solutioncombination

VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.